Selective regulation of IP3-receptor-mediated Ca2+ signaling and apoptosis by the BH4 domain of Bcl-2 versus Bcl-Xl

被引:0
|
作者
G Monaco
E Decrock
H Akl
R Ponsaerts
T Vervliet
T Luyten
M De Maeyer
L Missiaen
C W Distelhorst
H De Smedt
J B Parys
L Leybaert
G Bultynck
机构
[1] Laboratory of Molecular and Cellular Signaling,Department of Molecular Cell Biology
[2] Campus Gasthuisberg O/N-1 bus 802,Department of Basic Medical Sciences
[3] Herestraat 49,Department of Chemistry
[4] BE-3000 Leuven,Departments of Medicine and Pharmacology
[5] Belgium,undefined
[6] Physiology Group,undefined
[7] Faculty of Medicine and Health Sciences,undefined
[8] Ghent University,undefined
[9] Biomolecular Modelling,undefined
[10] Biochemistry,undefined
[11] Molecular and Structural Biology Section,undefined
[12] Celestijnenlaan 200G bus 2403,undefined
[13] BE-3001 Heverlee,undefined
[14] Belgium,undefined
[15] Comprehensive Cancer Center,undefined
[16] Case Western Reserve University,undefined
来源
关键词
apoptosis; antiapoptotic Bcl-2-family members; calcium signaling; endoplasmic reticulum; intracellular Ca; -release channels;
D O I
暂无
中图分类号
学科分类号
摘要
Antiapoptotic B-cell lymphoma 2 (Bcl-2) targets the inositol 1,4,5-trisphosphate receptor (IP3R) via its BH4 domain, thereby suppressing IP3R Ca2+-flux properties and protecting against Ca2+-dependent apoptosis. Here, we directly compared IP3R inhibition by BH4-Bcl-2 and BH4-Bcl-Xl. In contrast to BH4-Bcl-2, BH4-Bcl-Xl neither bound the modulatory domain of IP3R nor inhibited IP3-induced Ca2+ release (IICR) in permeabilized and intact cells. We identified a critical residue in BH4-Bcl-2 (Lys17) not conserved in BH4-Bcl-Xl (Asp11). Changing Lys17 into Asp in BH4-Bcl-2 completely abolished its IP3R-binding and -inhibitory properties, whereas changing Asp11 into Lys in BH4-Bcl-Xl induced IP3R binding and inhibition. This difference in IP3R regulation between BH4-Bcl-2 and BH4-Bcl-Xl controls their antiapoptotic action. Although both BH4-Bcl-2 and BH4-Bcl-Xl had antiapoptotic activity, BH4-Bcl-2 was more potent than BH4-Bcl-Xl. The effect of BH4-Bcl-2, but not of BH4-Bcl-Xl, depended on its binding to IP3Rs. In agreement with the IP3R-binding properties, the antiapoptotic activity of BH4-Bcl-2 and BH4-Bcl-Xl was modulated by the Lys/Asp substitutions. Changing Lys17 into Asp in full-length Bcl-2 significantly decreased its binding to the IP3R, its ability to inhibit IICR and its protection against apoptotic stimuli. A single amino-acid difference between BH4-Bcl-2 and BH4-Bcl-Xl therefore underlies differential regulation of IP3Rs and Ca2+-driven apoptosis by these functional domains. Mutating this residue affects the function of Bcl-2 in Ca2+ signaling and apoptosis.
引用
收藏
页码:295 / 309
页数:14
相关论文
共 50 条
  • [31] Modulation of Ca2+signaling by antiapoptotic Bcl-2 versus Bcl-xL: From molecular mechanisms to relevance for cancer cell survival
    Rosa, Nicolas
    Speelman-Rooms, Femke
    Parys, Jan B.
    Bultynck, Geert
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2022, 1877 (06):
  • [32] BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models
    Tamara Vervloessem
    Binu K. Sasi
    Elena Xerxa
    Spyridoula Karamanou
    Justin Kale
    Rita M. La Rovere
    Supriya Chakraborty
    Flore Sneyers
    Meike Vogler
    Anastassios Economou
    Luca Laurenti
    David W. Andrews
    Dimitar G. Efremov
    Geert Bultynck
    Cell Death & Disease, 11
  • [33] The selective Bcl-2 inhibitor venetoclax, a BH3 mimetic, does not dysregulate intracellular Ca2+ signaling
    Vervloessem, Tamara
    Ivanova, Hristina
    Luyten, Tomas
    Parys, Jan B.
    Bultynck, Geert
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2017, 1864 (06): : 968 - 976
  • [34] The regulation of the ER-mitochondria-Ca2+cross-talk by Bcl-2 and Bcl-XL: A new scenario for the development of selective tools in oncology?
    Akl, Haidar
    Monaco, Giovanni
    Decrock, Elke
    La Rovere, Rita
    Welkenhuyzen, Kirsten
    Luyten, Tomas
    Kiviluoto, Santeri
    Vervliet, Tim
    Molgo, Jordi
    Missiaen, Ludwig
    Mikoshiba, Katsuhiko
    Leybaert, Luc
    Parys, Jan B.
    De Smedt, Humbert
    Distelhorst, Clark W.
    Bultynck, Geert
    CANCER RESEARCH, 2013, 73
  • [35] Selective BH3-mimetics targeting BCL-2, BCL-XL or MCL-1 induce severe mitochondrial perturbations
    Henz, Kristina
    Al-Zebeeby, Aoula
    Basoglu, Marion
    Fulda, Simone
    Cohen, Gerald M.
    Varadarajan, Shankar
    Vogler, Meike
    BIOLOGICAL CHEMISTRY, 2019, 400 (02) : 181 - 185
  • [36] BCL2L12 contains a BH3 like motif capable of antagonising Bcl-2 and Bcl-xL and is proapoptotic
    Hickman, John
    Licznar, A.
    Le Toumelin, G.
    Mazars, A.
    Terradillos, O.
    Guasconi, G.
    Cauquil, N.
    Studeny, A.
    Geneste, O.
    Murray, J.
    Dokurno, P.
    Rain, J-C
    CANCER RESEARCH, 2009, 69
  • [37] Retinamide-induced apoptosis in glioblastomas is associated with down-regulation of Bcl-xL and Bcl-2 proteins
    Lytle, RA
    Jiang, ZH
    Zheng, X
    Higashikubo, R
    Rich, KM
    JOURNAL OF NEURO-ONCOLOGY, 2005, 74 (03) : 225 - 232
  • [38] Retinamide-Induced Apoptosis in Glioblastomas is Associated with Down-Regulation of Bcl-xL and Bcl-2 Proteins
    Richard A. Lytle
    Zhihong Jiang
    Xiao Zheng
    Ryuji Higashikubo
    Keith M. Rich
    Journal of Neuro-Oncology, 2005, 74 : 225 - 232
  • [39] The Bcl-2/Bcl-xL inhibitor BH3I-2′ affects the dynamics and subcellular localization of sumoylated proteins
    Plourde, Melodie B.
    Morchid, Aida
    Iranezereza, Lolita
    Berthoux, Lionel
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2013, 45 (04): : 826 - 835
  • [40] Regulation of B cell apoptosis by Bcl-2 and Bcl-XL and its role in the development of autoimmune diseases (Review)
    Lopez-Hoyos, M
    Carrio, R
    Merino, J
    Merino, R
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 1998, 1 (02) : 475 - 483